{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:24:25Z","timestamp":1793388265669,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T00:00:00Z","timestamp":1281484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10787-010-0052-6","type":"journal-article","created":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T00:56:07Z","timestamp":1281401767000},"page":"223-232","source":"Crossref","is-referenced-by-count":12,"title":["Licofelone attenuates MPTP-induced neuronal toxicity: behavioral, biochemical and cellular evidence"],"prefix":"10.1007","volume":"18","author":[{"given":"Amit","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,11]]},"reference":[{"key":"52_CR1","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/0140-6736(91)92989-F","volume":"337","author":"Y Agid","year":"1991","unstructured":"Agid Y (1991) Parkinson\u2019s disease: pathophysiology. Lancet 337:1321\u20131324","journal-title":"Lancet"},{"key":"52_CR2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/WNR.0b013e3282fb7898","volume":"19","author":"JA Aguirre","year":"2008","unstructured":"Aguirre JA, Leo G, Cueto R, Andbjer B, Naylor A, Medhurst AD et al (2008) The novel cyclooxygenase-2 inhibitor GW637185x protects against l-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine toxicity. Neuroreport 19:657\u2013660","journal-title":"Neuroreport"},{"key":"52_CR3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1172\/JCI107236","volume":"52","author":"BM Babior","year":"1973","unstructured":"Babior BM, Kipner RS, Cerutte JT (1973) Biological defense mechanism. The production by leukocytes of superoxide, a potential bacterial agent. J Clin Invest 52:741\u2013744","journal-title":"J Clin Invest"},{"key":"52_CR4","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/mds.21552","volume":"22","author":"AL Bartels","year":"2007","unstructured":"Bartels AL, Leenders KL (2007) Neuroinflammation in the pathophysiology of Parkinson\u2019s disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord 22:1852\u20131856","journal-title":"Mov Disord"},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1046\/j.1471-4159.1999.0731127.x","volume":"73","author":"SB Berman","year":"1999","unstructured":"Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson\u2019s disease. J Neurochem 73:1127\u20131137","journal-title":"J Neurochem"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1572-0241.2004.04133.x","volume":"99","author":"P Bias","year":"2004","unstructured":"Bias P, Buchner A, Klesser B, Laufer S (2004) The gastrointestinal tolerability of the LOX\/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from randomized, controlled trial. Am J Gastroenterol 99:611\u2013618","journal-title":"Am J Gastroenterol"},{"key":"52_CR7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0090-6980(81)90036-8","volume":"22","author":"MA Bray","year":"1981","unstructured":"Bray MA, Ford-Hutchinson AW, Smith MJ (1981) Leukotriene B4: an inflammatory mediator in vivo. Prostaglandins 22:213\u2013222","journal-title":"Prostaglandins"},{"key":"52_CR8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1073\/pnas.87.2.682","volume":"87","author":"DS Bredt","year":"1990","unstructured":"Bredt DS, Snyder SH (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 87:682\u2013685","journal-title":"Proc Natl Acad Sci USA"},{"key":"52_CR9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.neuroscience.2006.04.022","volume":"141","author":"M Chalimoniuk","year":"2006","unstructured":"Chalimoniuk M, Lukacova N, Marsala J, Langfort J (2006) Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 141:1033\u20131046","journal-title":"Neuroscience"},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.taap.2007.02.002","volume":"220","author":"DA Drechsel","year":"2007","unstructured":"Drechsel DA, Liang LP, Patel M (2007) 1-Methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons. Toxicol Appl Pharmacol 220:341\u2013348","journal-title":"Toxicol Appl Pharmacol"},{"key":"52_CR11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","volume":"82","author":"GL Ellman","year":"1959","unstructured":"Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70\u201377","journal-title":"Arch Biochem Biophys"},{"key":"52_CR12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jocn.2007.02.095","volume":"15","author":"M Etminan","year":"2008","unstructured":"Etminan M, Carleton BC, Samii A (2008) Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 15:576\u2013577","journal-title":"J Clin Neurosci"},{"key":"52_CR13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0304-3940(02)00704-8","volume":"329","author":"ZH Feng","year":"2002","unstructured":"Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B et al (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329:354\u2013358","journal-title":"Neurosci Lett"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0006-2952(01)00747-X","volume":"62","author":"S Fiorucci","year":"2001","unstructured":"Fiorucci S, Meli R, Bucci M, Cirino G (2001) Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy. Biochem Pharmacol 62:1433\u20131438","journal-title":"Biochem Pharmacol"},{"key":"52_CR15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0021-9258(18)57021-6","volume":"177","author":"AG Gornall","year":"1949","unstructured":"Gornall AG, Bardawill CJ, David MM (1949) Determination of serum proteins by means of the biuret reaction. J Biol Chem 177:751\u2013766","journal-title":"J Biol Chem"},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pbb.2009.07.018","volume":"94","author":"A Gupta","year":"2009","unstructured":"Gupta A, Dhir A, Kumar A, Kulkarni SK (2009) Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats. Pharmacol Biochem Behav 94:219\u2013226","journal-title":"Pharmacol Biochem Behav"},{"key":"52_CR17","first-page":"577","volume":"48","author":"A Gupta","year":"2010","unstructured":"Gupta A, Dhir A, Kumar A, Kulkarni SK (2010) Effect of preferential cyclooxygenase-2 (COX-2)-inhibitor against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced striatal lesions in rats: behavioral, biochemical and histological evidences. Indian J Exp Biol 48:577\u2013585","journal-title":"Indian J Exp Biol"},{"key":"52_CR18","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1471-4159.1992.tb10990.x","volume":"59","author":"B Halliwell","year":"1992","unstructured":"Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59:1609\u20131623","journal-title":"J Neurochem"},{"key":"52_CR19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1046\/j.1471-4159.1995.64020919.x","volume":"64","author":"TG Hastings","year":"1995","unstructured":"Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64:919\u2013924","journal-title":"J Neurochem"},{"key":"52_CR20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2003.tb07478.x","volume":"991","author":"EC Hirsch","year":"2003","unstructured":"Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson\u2019s disease. Ann N Y Acad Sci 991:214\u2013228","journal-title":"Ann N Y Acad Sci"},{"key":"52_CR21","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1471-4159.2006.04327.x","volume":"100","author":"RL Hunter","year":"2007","unstructured":"Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC et al (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100:1375\u20131386","journal-title":"J Neurochem"},{"key":"52_CR60","doi-asserted-by":"crossref","unstructured":"Kalonia H, Kumar P, Kumar A, Nehru B (2009) Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats. Inflammopharmacol 17:211\u2013219","DOI":"10.1007\/s10787-009-0012-1"},{"key":"52_CR22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/emm.2006.40","volume":"38","author":"YS Kim","year":"2006","unstructured":"Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson\u2019s disease. Exp Mol Med 38:333\u2013347","journal-title":"Exp Mol Med"},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0076-6879(67)10055-4","volume":"10","author":"TE King","year":"1967","unstructured":"King TE, Howard RL (1967) Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol 10:275\u2013284","journal-title":"Methods Enzymol"},{"key":"52_CR24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1006\/mcne.2000.0914","volume":"16","author":"C Knott","year":"2000","unstructured":"Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson\u2019s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16:724\u2013739","journal-title":"Mol Cell Neurosci"},{"key":"52_CR25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/156802607779941305","volume":"7","author":"SK Kulkarni","year":"2007","unstructured":"Kulkarni SK, Singh VP (2007) Licofelone\u2014a novel analgesic and anti-inflammatory agent. Curr Top Med Chem 7:251\u2013263","journal-title":"Curr Top Med Chem"},{"key":"52_CR26","first-page":"629","volume":"44","author":"S Laufer","year":"1994","unstructured":"Laufer S, Tries S, Augustin J, Dannhardt G (1994) Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforschung 44:629\u2013636","journal-title":"Arzneimittelforschung"},{"key":"52_CR27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199009063231006","volume":"323","author":"RA Lewis","year":"1990","unstructured":"Lewis RA, Austen KF, Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 323:645\u2013655","journal-title":"N Engl J Med"},{"key":"52_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2008.08.053","volume":"445","author":"Z Li","year":"2008","unstructured":"Li Z, Choi DY, Shin EJ, Hunter RL, Jin CH, Wie MB et al (2008) Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett 445:1\u20136","journal-title":"Neurosci Lett"},{"key":"52_CR29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/ard.62.6.501","volume":"62","author":"J Martel-Pelletier","year":"2003","unstructured":"Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP (2003) Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 62:501\u2013509","journal-title":"Ann Rheum Dis"},{"key":"52_CR30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cnr.2006.09.006","volume":"6","author":"RL Mosley","year":"2006","unstructured":"Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K et al (2006) Neuroinflammation, oxidative stress and the pathogenesis of Parkinson\u2019s disease. Clin Neurosci Res 6:261\u2013281","journal-title":"Clin Neurosci Res"},{"key":"52_CR31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363","journal-title":"J Immunol Methods"},{"key":"52_CR32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","volume":"95","author":"H Ohkawa","year":"1979","unstructured":"Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351\u2013358","journal-title":"Anal Biochem"},{"key":"52_CR33","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1073\/pnas.93.10.4565","volume":"93","author":"S Przedborski","year":"1996","unstructured":"Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93:4565\u20134571","journal-title":"Proc Natl Acad Sci USA"},{"key":"52_CR34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainres.2004.05.095","volume":"1019","author":"A Przyby\u0142kowski","year":"2004","unstructured":"Przyby\u0142kowski A, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A, Cz\u0142onkowska A (2004) Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson\u2019s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Res 1019:144\u2013151","journal-title":"Brain Res"},{"key":"52_CR35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0014-2999(00)00196-5","volume":"395","author":"V Raghavendra","year":"2000","unstructured":"Raghavendra V, Agrewala JN, Kulkarni SK (2000) Melatonin reversal of lipopolysaccharide-induced thermal and behavioral hyperalgesia in mice. Eur J Pharmacol 395:15\u201321","journal-title":"Eur J Pharmacol"},{"key":"52_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/1-4020-5688-5_1","volume":"42","author":"KD Rainsford","year":"2007","unstructured":"Rainsford KD (2007) Anti-inflammatory drugs in the 21st century. Subcell Biochem 42:3\u201327","journal-title":"Subcell Biochem"},{"key":"52_CR37","first-page":"882","volume":"40","author":"A Singh","year":"2002","unstructured":"Singh A, Kulkarni SK (2002) Role of adenosine in drug-induced catatonia. Indian J Exp Biol 40:882\u2013888","journal-title":"Indian J Exp Biol"},{"key":"52_CR38","first-page":"247","volume":"43","author":"VP Singh","year":"2005","unstructured":"Singh VP, Patil CS, Kulkarni SK (2005) Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation. Indian J Exp Biol 43:247\u2013253","journal-title":"Indian J Exp Biol"},{"key":"52_CR39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1472-8206.2005.00387.x","volume":"20","author":"VP Singh","year":"2006","unstructured":"Singh VP, Patil CS, Kulkarni SK (2006) Anti-inflammatory effect of licofelone against various inflammatory challenges. Fundam Clin Pharmacol 20:65\u201371","journal-title":"Fundam Clin Pharmacol"},{"key":"52_CR40","doi-asserted-by":"crossref","first-page":"15466","DOI":"10.1016\/S0021-9258(17)36277-4","volume":"260","author":"A Slivka","year":"1985","unstructured":"Slivka A, Cohen G (1985) Hydroxyl radical attack on dopamine. J Biol Chem 260:15466\u201315472","journal-title":"J Biol Chem"},{"key":"52_CR41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molbrainres.2004.09.017","volume":"134","author":"RJ Smeyne","year":"2005","unstructured":"Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson\u2019s disease. Brain Res Mol Brain Res 134:57\u201366","journal-title":"Brain Res Mol Brain Res"},{"key":"52_CR42","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.86.4.1398","volume":"86","author":"MB Spina","year":"1989","unstructured":"Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 86:1398\u20131400","journal-title":"Proc Natl Acad Sci USA"},{"key":"52_CR43","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1471-4159.2005.03566.x","volume":"96","author":"K Sriram","year":"2006","unstructured":"Sriram K, Miller DB, O\u2019Callaghan P (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 96:706\u2013718","journal-title":"J Neurochem"},{"key":"52_CR44","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1073\/pnas.0837397100","volume":"100","author":"P Teismann","year":"2003","unstructured":"Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson\u2019s disease neurodegeneration. Proc Natl Acad Sci USA 100:5473\u20135478","journal-title":"Proc Natl Acad Sci USA"},{"key":"52_CR45","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/NEN.0b013e31818e5e99","volume":"67","author":"S Theodore","year":"2008","unstructured":"Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted overexpression of human alphasynuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67:1149\u20131158","journal-title":"J Neuropathol Exp Neurol"},{"key":"52_CR46","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1471-4159.1993.tb13610.x","volume":"61","author":"KF Tipton","year":"1993","unstructured":"Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191\u20131206","journal-title":"J Neurochem"},{"key":"52_CR47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1163\/156856001300248380","volume":"9","author":"S Tries","year":"2001","unstructured":"Tries S, Laufer S (2001) The pharmacological profile of ML 3000: a new pyrrolizine derivative inhibiting the enzymes cyclooxygenase and 5-lipoxygenase. Inflammopharmacology 9:113\u2013124","journal-title":"Inflammopharmacology"},{"key":"52_CR48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/PL00000285","volume":"51","author":"S Tries","year":"2002","unstructured":"Tries S, Neupert W, Laufer S (2002) The mechanism of action of the new anti-inflammatory compound ML3000: inhibition of 5-LOX and COX-1\/2. Inflamm Res 51:135\u2013143","journal-title":"Inflamm Res"},{"key":"52_CR49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn1100","volume":"4","author":"M Vila","year":"2003","unstructured":"Vila M, Przedborski S (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4:365\u2013375","journal-title":"Nat Rev Neurosci"},{"key":"52_CR50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1471-4159.2008.05604.x","volume":"107","author":"M Vila","year":"2008","unstructured":"Vila M, Ramonet D, Perier C (2008) Mitochondrial alterations in Parkinson\u2019s disease: new clues. J Neurochem 107:317\u2013328","journal-title":"J Neurochem"},{"key":"52_CR51","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1212\/01.wnl.0000279519.99344.ad","volume":"69","author":"AD Wahner","year":"2007","unstructured":"Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2007) Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69:1836\u20131842","journal-title":"Neurology"},{"key":"52_CR52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10072-008-0986-2","volume":"29","author":"H Yokoyama","year":"2008","unstructured":"Yokoyama H, Kuroiwa H, Yano R, Araki T (2008) Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson\u2019s disease. Neurol Sci 29:293\u2013301","journal-title":"Neurol Sci"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-010-0052-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10787-010-0052-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-010-0052-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T06:23:47Z","timestamp":1636007027000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10787-010-0052-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,11]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s10787-010-0052-6","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,11]]}}}